Early experience of seven hepatocellular carcinoma cases treated with regorafenib

Regorafenib became second‐line treatment for the patients with sorafenib refractory. In our study, two patients could not continue regorafenib for its adverse effects. It was suggested that appropriate use criteria of regorafenib should be observed and manage adverse effects earlier.

Detalles Bibliográficos
Autores principales: Uchikawa, Shinsuke, Kawaoka, Tomokazu, Aikata, Hiroshi, Kodama, Kenichiro, Inagaki, Yuki, Hatooka, Masahiro, Morio, Kei, Nakahara, Takashi, Murakami, Eisuke, Hiramatsu, Akira, Tsuge, Masataka, Imamura, Michio, Kawakami, Yoshiiku, Chayama, Kazuaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6230610/
https://www.ncbi.nlm.nih.gov/pubmed/30455925
http://dx.doi.org/10.1002/ccr3.1791
_version_ 1783370110196514816
author Uchikawa, Shinsuke
Kawaoka, Tomokazu
Aikata, Hiroshi
Kodama, Kenichiro
Inagaki, Yuki
Hatooka, Masahiro
Morio, Kei
Nakahara, Takashi
Murakami, Eisuke
Hiramatsu, Akira
Tsuge, Masataka
Imamura, Michio
Kawakami, Yoshiiku
Chayama, Kazuaki
author_facet Uchikawa, Shinsuke
Kawaoka, Tomokazu
Aikata, Hiroshi
Kodama, Kenichiro
Inagaki, Yuki
Hatooka, Masahiro
Morio, Kei
Nakahara, Takashi
Murakami, Eisuke
Hiramatsu, Akira
Tsuge, Masataka
Imamura, Michio
Kawakami, Yoshiiku
Chayama, Kazuaki
author_sort Uchikawa, Shinsuke
collection PubMed
description Regorafenib became second‐line treatment for the patients with sorafenib refractory. In our study, two patients could not continue regorafenib for its adverse effects. It was suggested that appropriate use criteria of regorafenib should be observed and manage adverse effects earlier.
format Online
Article
Text
id pubmed-6230610
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-62306102018-11-19 Early experience of seven hepatocellular carcinoma cases treated with regorafenib Uchikawa, Shinsuke Kawaoka, Tomokazu Aikata, Hiroshi Kodama, Kenichiro Inagaki, Yuki Hatooka, Masahiro Morio, Kei Nakahara, Takashi Murakami, Eisuke Hiramatsu, Akira Tsuge, Masataka Imamura, Michio Kawakami, Yoshiiku Chayama, Kazuaki Clin Case Rep Case Reports Regorafenib became second‐line treatment for the patients with sorafenib refractory. In our study, two patients could not continue regorafenib for its adverse effects. It was suggested that appropriate use criteria of regorafenib should be observed and manage adverse effects earlier. John Wiley and Sons Inc. 2018-10-11 /pmc/articles/PMC6230610/ /pubmed/30455925 http://dx.doi.org/10.1002/ccr3.1791 Text en © 2018 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Uchikawa, Shinsuke
Kawaoka, Tomokazu
Aikata, Hiroshi
Kodama, Kenichiro
Inagaki, Yuki
Hatooka, Masahiro
Morio, Kei
Nakahara, Takashi
Murakami, Eisuke
Hiramatsu, Akira
Tsuge, Masataka
Imamura, Michio
Kawakami, Yoshiiku
Chayama, Kazuaki
Early experience of seven hepatocellular carcinoma cases treated with regorafenib
title Early experience of seven hepatocellular carcinoma cases treated with regorafenib
title_full Early experience of seven hepatocellular carcinoma cases treated with regorafenib
title_fullStr Early experience of seven hepatocellular carcinoma cases treated with regorafenib
title_full_unstemmed Early experience of seven hepatocellular carcinoma cases treated with regorafenib
title_short Early experience of seven hepatocellular carcinoma cases treated with regorafenib
title_sort early experience of seven hepatocellular carcinoma cases treated with regorafenib
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6230610/
https://www.ncbi.nlm.nih.gov/pubmed/30455925
http://dx.doi.org/10.1002/ccr3.1791
work_keys_str_mv AT uchikawashinsuke earlyexperienceofsevenhepatocellularcarcinomacasestreatedwithregorafenib
AT kawaokatomokazu earlyexperienceofsevenhepatocellularcarcinomacasestreatedwithregorafenib
AT aikatahiroshi earlyexperienceofsevenhepatocellularcarcinomacasestreatedwithregorafenib
AT kodamakenichiro earlyexperienceofsevenhepatocellularcarcinomacasestreatedwithregorafenib
AT inagakiyuki earlyexperienceofsevenhepatocellularcarcinomacasestreatedwithregorafenib
AT hatookamasahiro earlyexperienceofsevenhepatocellularcarcinomacasestreatedwithregorafenib
AT moriokei earlyexperienceofsevenhepatocellularcarcinomacasestreatedwithregorafenib
AT nakaharatakashi earlyexperienceofsevenhepatocellularcarcinomacasestreatedwithregorafenib
AT murakamieisuke earlyexperienceofsevenhepatocellularcarcinomacasestreatedwithregorafenib
AT hiramatsuakira earlyexperienceofsevenhepatocellularcarcinomacasestreatedwithregorafenib
AT tsugemasataka earlyexperienceofsevenhepatocellularcarcinomacasestreatedwithregorafenib
AT imamuramichio earlyexperienceofsevenhepatocellularcarcinomacasestreatedwithregorafenib
AT kawakamiyoshiiku earlyexperienceofsevenhepatocellularcarcinomacasestreatedwithregorafenib
AT chayamakazuaki earlyexperienceofsevenhepatocellularcarcinomacasestreatedwithregorafenib

Ejemplares similares